Search results
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 2 days agoPreliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma ...
Bio-Path Holdings Inc (BPTH) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...
GuruFocus.com via Yahoo Finance· 1 day agoCompletion of the second dose cohort in the Phase 1/1B clinical trial of BP1002 for treating refractory relapsed AML, including venetoclax-resistant patients, showing no dose-limiting ...
Alimera Sciences (NASDAQ:ALIM) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPS
ETF DAILY NEWS· 9 hours agoAlimera Sciences (NASDAQ:ALIM – Get Free Report) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing analysts’ consensus ...
MEI Pharma (NASDAQ:MEIP) Coverage Initiated at StockNews.com
ETF DAILY NEWS· 13 hours agoEquities researchers at StockNews.com began coverage on shares of MEI Pharma (NASDAQ:MEIP – Get Free Report) in a report released on Wednesday. The brokerage set a “buy” rating on the stock.
Grey’s Anatomy Richard Webber star knows alcoholism 'first hand' thanks to dad
Daily Express· 1 day agoThe 69-year-old went on to explain how viewers have also reacted to Richard’s ongoing battle with...
My doctor told me I had dandruff but the lumps were cancer
Yahoo Life UK· 1 day agoI can’t tell you how quickly the time has flown by but mentally, the illness has affected me badly....
Short Interest in Curis, Inc. (NASDAQ:CRIS) Grows By 13.3%
ETF DAILY NEWS· 9 hours agoCuris, Inc. (NASDAQ:CRIS – Get Free Report) saw a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 67,300 shares, a growth ...
FDA Broadens Breyanzi's Follicular Lymphoma Indication
Medscape· 1 day agoThe overall response rate to the CAR T therapy was 95.7% in phase 2 testing.
Arcellx (NASDAQ:ACLX) Earns Outperform Rating from Analysts at Evercore ISI
ETF DAILY NEWS· 13 hours agoEvercore ISI started coverage on shares of Arcellx (NASDAQ:ACLX – Free Report) in a research note released on Tuesday morning, Benzinga reports. A number of other research analysts have also ...
No Improvement in OS With Atezolizumab in Relapsing TNBC
Medscape· 1 day agoEarly relapsing disease has again shown the limitations of immunotherapy in triple-negative breast...